Developing RNAi Therapeutics (Part III)

An interview with Patrick Lu, Founder and CEO of Sirnaomics, Inc.



00:05:48 - Uploaded by Essinova on September 14, 2009

Essinova host BeiBei Song interviewed Patrick Lu, Ph.D., Founder and CEO of Sirnaomics, Inc, about the science and business of developing RNAi therapeutics during the IBC Oligonucleotide Therapeutics conference in Boston.

In this last segment, Dr. Lu addresses IP issues specific to RNAi therapeutic development and Sirnaomics' IP strategy. He also shares his experience operating in China, commenting on various advantages China offers to developing cutting edge technologies such as siRNA, from efficiency and talent to financial resources.

Tags: RNAi, siRNA, miRNA, oligonucleotides, Sirnaomics, Patrick Lu, IBC, DDD, China, Suzhou


There are 0 comments. You must be logged in to comment.

Therapeutics & Vaccines

 photo Essinova-Brain-and-Mind-banner_iStock_000004422514Medium.jpg

 photo Essinova_Art-and-Science-banner_PIA09962.jpg